RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsMay 03, 2024 -
The proportion of US$ 10 Blillion deals are increasing versus the US$ 5 Billion "bolt-on" deals. (10:35 timestamp)
More competition for late stage biotech companies resulting in premium prices. (13:30 timestamp)
https://www.fiercepharma.com/deals/closer-look-2023s-top-biopharma-deals-and-what-lies-
According to the law firm of Morgan Lewis of Boston, MA., " In 2024, we expect M&A will more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors of the life sciences industry. We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot but see the potential for one or more deals in the $20 billion to $40 billion range before year-end."
https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=36023821
https://www.morganlewis.com/pubs/2024/05/trends-and-tips-for-navigating-life-sciences-m-a-in-2024